We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
BioView and Transgenomic Enter into Distribution Agreement
News

BioView and Transgenomic Enter into Distribution Agreement

BioView and Transgenomic Enter into Distribution Agreement
News

BioView and Transgenomic Enter into Distribution Agreement

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "BioView and Transgenomic Enter into Distribution Agreement"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

BioView Ltd. of Israel and Transgenomic, Inc. of Nebraska announced that they have entered into an agreement allowing Transgenomic to distribute BioView's family of Scanning and Analysis Workstations in selected Western European countries and Scandinavia.

Transgenomic's European sales and support organization will market, sell and service the instruments. BioView's products include the Duet, Allegro and Accord automated workstations for the scanning and classification of cells via fluorescence in-situ hybridization (FISH) and brightlight microscopy. The results of the scan are reviewed on the BioView Solo offline workstation for the final report.

The BioView products are intended for in-vitro diagnostic use as an aiding tool to the pathologist in the detection, classification and counting of cells of interest based on color, intensity, size, pattern, and shape.

The BioView products have applications for testing in hematological disorders, breast cancer studies for Her-2 neu gene amplification, bladder cancer screening and follow up using Vysis UroVysion™ Bladder Cancer Recurrence Kit and prenatal and postnatal genetic testing.

Dr. Opher Shapira, President and CEO of BioView Ltd., views this agreement as an opportunity for BioView to expand its market penetration in Europe in an efficient manner.

According to Shapira, "Transgenomic has a reputation amongst its European customer base for providing superior service and support. Following our success in the U.S. market, we believe that this agreement with Transgenomic will help establish us in a similar manner in the Western European and Scandinavian countries covered by this agreement."

Craig Tuttle, President and CEO of Transgenomic added, "We are very excited to add BioView's world-leading imaging platforms to our cytogenetics portfolio of products. These sophisticated imaging systems will complement our HANABI Metaphase Chromosome Harvester and spreader products and further expand our sales and service reach into cytogenetics and pathology laboratories across Europe."

Advertisement